From a technical perspective, the 23,000–23,100 zone remains an immediate resistance level for the Nifty, according to Ponmudi R, CEO of En...

Linux Laboratories has secured $70 million in equity funding from ChrysCapital and Tata Capital Healthcare Fund III. This investment involv...

Private equity firm ChrysCapital is set to acquire a significant stake in Linux Laboratories. This deal will see existing investor Tata Cap...

Indian stock markets closed lower on Monday, extending their losing streak for four weeks. Investor sentiment remained subdued due to risin...

Elara has initiated coverage on four pharmaceutical stocks, assigning Buy, Accumulate and Reduce ratings. Alkem Laboratories emerged as its...

Mankind Pharma's Q3 FY25 net profit declined 16% YoY to ₹385 crore despite a 24% revenue increase to ₹3,230 crore. Domestic revenues rose 1...

Mankind Pharma on Thursday said its consolidated net profit declined 16.5 per cent to Rs 384 crore in the third quarter ended December 31, ...

Indian pharmaceutical giants, Dr. Reddy's Labs and Mankind Pharma, reported impressive double-digit revenue growth in the September quarter...

Mankind Pharma witnessed a 29% surge in consolidated net profit, reaching Rs 658.88 crore in the second quarter, ending September 2024. Thi...

After initially cheering the deal, the stock market gave its thumbs-down to Mankind acquiring BSV at the premium valuations of eight times ...

Mankind Pharma has appointed Barclays and Deutsche Bank to arrange financing for its Rs 13,630 crore acquisition of Bharat Serums & Vaccine...

Mankind Pharma announced a ₹13,630 crore acquisition of Bharat Serums and Vaccines (BSV) to be funded through internal accruals and a mix o...

This is the largest acquisition by Mankind Pharma, India’s 4th largest pharma company by market share. A formal announcement regarding the ...

The domestic business reported a robust 14% YoY growth in the quarter. The secondary sales saw an impressive growth of 12.5%, thereby outpe...

The Delhi-headquartered drugmaker posted Rs 298 crore in the corresponding quarter of the previous year. Revenue rose 18% YoY to Rs 2579 cr...

Kotak Institutional Equities has initiated coverage on Mankind Pharma and given it an 'Add' rating with a target price of Rs 1,875. The bro...

Indian pharma company Mankind Pharma is set to open its IPO next week. The offer for sale of 40 million equity shares by promoters and othe...